A/Prof Philip Thompson
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
287 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy
DOI: 10.1182/bloodadvances.20260202432026
Journal article
Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective
DOI: 10.1182/bloodadvances.20260198712026
Journal article
Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study
DOI: 10.1158/2643-3230.BCD-25-03452026
Journal article
Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma
DOI: 10.1182/bloodadvances.20250185462026
Journal article
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
DOI: 10.1182/bloodadvances.20250166462026
Journal article
Balancing gains and pains: infections in the bispecific era
DOI: 10.1080/10428194.2025.25860822025
Journal article
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression
DOI: 10.1038/s41408-025-01382-x
RECENT SCHOLARLY WORKS
2025
Journal article
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
DOI: 10.1038/s41408-025-01236-62025
Journal article
Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders
DOI: 10.1182/blood-2025-21302025
Journal article
Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor lenalidomide [LEN]) and 2C (epcor R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial
DOI: 10.1182/blood-2025-1015